## Most Common Adverse Events Reported in a clinical study treating dogs diagnosed with osteosarcoma.

Adverse events reported were mostly mild to moderate and were typically transient in nature.

Procedure	Most Common Side Effects	Other Possible Risks
Vaccines	Inappetence, lethargy, vomiting, redness/swelling at the injection site	Fever or anaphylactic reactions may occur
T cell Infusate	Inappetence, gastrointestinal disturbances, fever, lethargy	Hypotension, hypothermia. Severe, life-threatening infusion reactions may occur which require immediate medical attention

The majority of adverse events seen with ECI have been Veterinary Cooperative Oncology Group (VCOG) grade 1 or 2. Most common adverse events include fever, lethargy, anorexia, pain, vomiting, and diarrhea. Transient dermatologic changes, such as erythema, dander, and seborrhea have been seen post-vaccination. Varying degrees of infusion reactions may be observed post T cell infusion. Less common but more severe infusion reactions can occur which can present signs similar to those seen with "Cytokine Release Syndrome" (CRS) and may include lethargy, pyrexia, renal impairment, vomiting, diarrhea, increased ALT/AST, life-threatening hypotension, and neutropenia. Medical intervention, along with supportive care, is required for serious infusion reactions and the management plan is detailed in the protocol. A single instance of lethal infusion reaction was observed prior to implementation of medical management plan. Most adverse reactions resolve on their own within approximately 72 hours, with supportive treatment, dose modification, or dose delay.